Clinical Analysis Of Haploidentical Hematopoietic Stem Cell Transplantation For Hematologic Malignancies

Objective: To investigate the clinical efficacy of haploidentical hematopoietic stem cell transplantation(haplo-HSCT)in patients with malignant hematopathy.Methods: A total of 48 patients were enrolled in this study.The granulocyte colony-stimulating factor(G-CSF)was used to mobilize peripheral blood stem cells as grafts without in vitro T cell depletion.Results: All the 48 patients achieved neutrophil recovery and megakaryocyte reconstitution.The median time of neutrophil engraftment was 14(9~38)d.The median time of platelet engraftment was 16.5(9~49)d.The cumulative incidence of actue GVHD(aGVHD)on the first 100 days after transplantation(+100d)was 16.5%,and that of grades III-IV aGVHD was 6.7%.43 patients were survived beyonded the +100d,the 2-year cumulative incidence of total chronic GVHD(cGVHD)was 28.6%,and that of extensive cGVHD was 12.6%.The 2-year cumulative incidences of relapse and nonrelapse mortality(NRM)were 23.7% and 30.2%,respectively.The cumulative incidences of overall survival(OS)anddisease-free survival(DFS)at 2 and 3 years were 52.6% and 44.5%,37.5%and 33.8%,respectively.Conclusion: The results showed that haplo-HSCT without in vitro T cell depletion is an effective method for hematologic malignancies,and there is no significant difference in the effect of grafts with peripheral blood stem cells and bone marrow + peripheral blood stem cells in haplo-HSCT.